Aldeyra Therapeutics shares rise 10.69% intraday after FDA extends PDUFA date for reproxalap NDA to March 2026.

Aldeyra Therapeutics surged 10.69% intraday after being highlighted in a Simply Wall St article featuring it as a promising penny stock. The piece emphasized the company’s reduced losses, sufficient cash runway, and the FDA’s extension of the PDUFA target action date for reproxalap’s New Drug Application to March 2026, citing additional data submissions. These developments, combined with the broader market’s positive momentum in tech and biotech sectors, likely fueled investor optimism. The article’s focus on Aldeyra’s financial health and regulatory progress aligned with its intraday rally, positioning it as a speculative growth candidate amid favorable market conditions.